Charlotte, N.C. – Early detection rates for lung cancer fall significantly below that of other cancers, leading to a poorer prognosis upon diagnosis. Presbyterian Cancer Center hopes to be part of the momentum that changes this trend through their participation in an international lung cancer screening research trial.
This research trial, known as the International Early Lung Cancer Action Program (I-ELCAP), is based upon research findings from the National Lung Screening Trial that screening with low-dose CT reduces lung cancer mortality by 20 percent over chest X-ray. Participants in the research trial may self refer and must have extensive smoking history (one pack/day for 30 years; two packs/day for 15 years), family history or significant exposure to second-hand smoke to be eligible. Presbyterian Cancer Center is the only site offering this research trial within a three-state radius.
The purpose of the I-ELCAP study is to study how well screening with low-dose CT increases the ability to detect lung cancer sooner, which consequently may increase cure rates for the disease. Results from this study may be used to support arguments to incorporate low-dose CT into preventive screenings for high-risk populations.
Local experts are optimistic about the impact of this trial. “It’s encouraging to see such momentum around this disease,” said James O’Brien, MD, Mecklenburg Radiology Associates. “Lung cancer has always lagged behind other cancers when it comes to standard screenings that could diagnosis and treat it before the onset of symptoms, and the I-ELCAP study could be a game-changer for lung cancer survivorship.”
Presbyterian Cancer Center will begin accepting patients for the I-ELCAP study on Mar. 1. To learn more or apply, visit www.presbyterian.org/screeningct or call 704-384-8980.